president Donald Trump were at the center of two high-profile meetings on Tuesday afternoon. It was a very busy afternoon for the 79-year-old, who first attended a meeting with Republican senators and then held a meeting in the Oval Office with NATO Secretary-General Mark Rutte.
Amid all this, concerns about Trump’s health remain as a report emerged earlier Tuesday that Trump may be taking an experimental weight-loss drug called retarglutide, made by drugmaker Eli Lilly, through the Federal Drug Administration’s “compassionate use” program. The program allows terminally ill patients to experimentally use drugs that have not yet been approved by the state for public use. U.S. Food and Drug Administration.
Claims First appeared on STAT News. The outlet said only one 79-year-old man had been approved to use retarglutide. It has been speculated that the patient may be Trump, but no confirmation has been provided. But the White House quickly pushed back on the report. Khushi DesaiThe White House deputy press secretary clarified this in an X post on Tuesday.
But rumors of Trump’s illness resurfaced on Wednesday after the US president was reportedly found to be having difficulty breathing while speaking to reporters after a meeting with Republican senators earlier on Wednesday. This video was shared by Medias Touch’s X account.
Here is the video:
The reporter behind White House report on retarglutide
STAT News reporter Lizzy Lawrence reported on the news that Trump may be a patient receiving Eli Lilly’s retarglutide drug. As White House Deputy Press Secretary Khush Desai The rumor was refuted on Xhe took aim at Lawrence, calling her a “non-serious gossip columnist.”
“As this must be made clear for Liz Lawrence, who has proven herself to be an unserious gossip columnist, this application is not appropriate for the President,” Desai wrote.
However, Desai didn’t stop there. He commented under Lizzy Lawrence’s post on X containing the report.
Referring to Lawrence’s reference to the White House not responding to a request for comment on the report, he wrote: “We should not dismiss baseless speculation just to not print the report. Any reporter with standards would understand that. “Are you now going to ask this stupid question to some 4 million Americans in this age group and then speculate that they are applicants?
Ted Lieu launches new attack on retarglutide report
One of Trump’s fiercest critics, California Sen. Ted Lieu, attacked the 79-year-old senator and the White House over reports that Trump may be using retarglutide. During a press conference on Wednesday, Liew raised the issue and asked the White team to “come clean.”
“What we do know is that there was a report of a person in the United States who took this particular new drug,” Liu said. “This is a 79-year-old man, very striking. This drug can only be given to someone under compassionate use terms. That means if someone is basically terminally ill, you can do it.
“So we need to know, did Donald Trump get this particular drug from Eli Lilly? Did he get it under that provision? If he did, why did that happen?”
